Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes.

Shih KC, Hsieh SH, Kwok CF, Hwu CM, Hsieh PS, Ho LT.

Growth Factors. 2013 Apr;31(2):66-73. doi: 10.3109/08977194.2013.772996. Epub 2013 Mar 1.

PMID:
23452315
2.
3.
4.

Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy.

Carroll MF, Hardy KJ, Burge MR, Schade DS.

Diabetes Technol Ther. 2002;4(5):595-605.

PMID:
12450440
5.
7.

Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients.

Bruttomesso D, Fongher C, Silvestri B, Barberio S, Marescotti MC, Iori E, Valerio A, Crazzolara D, Pianta A, Tiengo A, Del Prato S.

Diabetes Res Clin Pract. 2001 Feb;51(2):97-105.

PMID:
11165689
8.

Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.

Henriksen JE, Levin K, Thye-Rønn P, Alford F, Hother-Nielsen O, Holst JJ, Beck-Nielsen H.

Diabetes. 2000 Jul;49(7):1209-18.

PMID:
10909980
9.

Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.

Herrmann BL, Berg C, Vogel E, Nowak T, Renzing-Koehler K, Mann K, Saller B.

Horm Metab Res. 2004 Jan;36(1):54-61.

PMID:
14983408
10.

Glucose flux is normalized by compensatory hyperinsulinaemia in growth hormone-induced insulin resistance in healthy subjects, while skeletal muscle protein synthesis remains unchanged.

Nygren J, Thorell A, Brismar K, Essén P, Wernerman J, McNurlan MA, Garlick PJ, Ljungqvist O.

Clin Sci (Lond). 2002 Apr;102(4):457-64.

PMID:
11914108
11.

Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.

Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS, Jørgensen JO.

Clin Endocrinol (Oxf). 2008 Sep;69(3):452-61. doi: 10.1111/j.1365-2265.2008.03231.x. Epub 2008 Mar 10.

PMID:
18331610
12.

Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.

Laursen T, Jørgensen JO, Orskov H, Møller J, Harris AG, Christiansen JS.

Acta Endocrinol (Copenh). 1993 Nov;129(5):399-408.

PMID:
7506470
13.

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.

Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K.

Diabetes. 2003 Oct;52(10):2461-74.

14.
17.

Short-term effects of octreotide on glucose tolerance in patients with acromegaly.

Sato K, Takamatsu K, Hashimoto K.

Endocr J. 1995 Dec;42(6):739-45.

18.

Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.

King AB, Clark D, Wolfe GS.

Endocr Pract. 2012 Jul-Aug;18(4):558-62. doi: 10.4158/EP12042.OR.

PMID:
22548951
19.

Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.

Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, Mandarino L, Kashyap S, Belfort R, DeFronzo RA.

Am J Physiol Endocrinol Metab. 2002 Jun;282(6):E1360-8.

20.

Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes.

Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, Häring HU.

Diabetes Care. 2002 Nov;25(11):2065-73.

PMID:
12401758

Supplemental Content

Support Center